EP3810810
CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS
:
EP einkaleyfi: Þýðing ekki lögð inn:
18.6.2019:
6.3.2024:
19745306.1
:
17.6.2039
:
CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS
18.6.2019
6.3.2024
:
Takeda Pharmaceutical Company Limited:
1-1, Doshomachi 4-chome, Chuo-ku,, Osaka-shi, Osaka 541-0045, JP
:
OHASHI, Akihiro:
Fujisawa-shi, Kanagawa 251-0012, JP
:
IWAI, Kenichi:
Fujisawa-shi, Kanagawa 251-0012, JP
:
NAMBU, Tadahiro:
Fujisawa-shi, Kanagawa 251-0012, JP
:
YAMANAKA, Kazunori:
Fujisawa-shi, Kanagawa 2510012, JP
:
OTAKE, Kentaro:
Fujisawa-shi, Kanagawa 2510012, JP
:
NIU, Huifeng:
Cambridge, Massachusetts 02139, US
:
SHIN, Hyunjin:
Cambridge, Massachusetts 02139, US
:
KOENIG, Erik Michael:
Cambridge, Massachusetts 02139, US
:
201862686960 P:
19.6.2018:
US
:
JP2019025995:
18.6.2019
:
C12Q 1/6886, A61K 31/33, C07D 495/04, A61K 31/519, A61P 35/00